BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CRYSVITA (burosumab) is a monoclonal antibody (mAb) that inhibits FGF23, approved in 2018 for X-linked hypophosphatemia (XLH), a rare genetic disorder causing abnormally low phosphate levels. It is administered via subcutaneous injection and represents a paradigm shift from conventional phosphate supplementation by addressing the underlying disease mechanism. The drug targets patients with mutations in the PHEX gene who experience progressive bone disease, dental problems, and growth delays.
$25MPart D
PeakProduct is at peak commercial maturity with modest Part D claims reflecting rare disease prevalence; commercial teams are focused on maximizing penetration within the limited eligible patient population.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Effective Dosing of Burosumab in XLH
Started Nov 2025
120 enrolled
X-linked Hypophosphatemia (XLH)
Anti-FGF23 (Burosumab) in Adult Patients With XLH
Started Jan 2021
36 enrolled
X-linked Hypophosphatemia
Burosumab for CSHS
Started Jul 2019
1 enrolled
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)Epidermal Nevus Syndrome
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
Started Jan 2018
1 enrolled
HypophosphatemiaHypophosphatemic RicketsPain, Chronic
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
Started Sep 2016
61 enrolled
X-Linked Hypophosphatemia
Worked on CRYSVITA at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.